Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic and non-genetic factors influencing the therapeutic response of valproic acid in pediatric epileptic patients.

Personalized medicine - 1 Feb 2025

Wu Changsong, Zheng Jianghuan, Pan Yanling, Tao Ruyu, Zhong Zhijun, Qian Chaozhi, Liang Heng, Wu Haijun

Abstract excerpt

AIMS: Considerable inter-individual variability in the efficacy of valproic acid (VPA) has been reported, with approximately 20-45% of patients failing to achieve satisfactory seizure control after VPA monotherapy. The aim of this study was to investigate the influence of non-genetic and genetic factors on 12-month VPA-response in a cohort of 194 pediatric patients. MATERIALS & METHODS: Trough concentrations were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants
Share to Child, Preschool

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epilepsy

Share to Infant

Share to Multidrug Resistance-Associated Protein 2

Share to Receptors, GABA-A

Share to Treatment Outcome

Share to Valproic Acid

Source

Identifiers

PMID: 39711059
DOI: 10.1080/17410541.2024.2441655

Genes

GABRA1
SLC16A1
ABCC2
ACADM

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic and non-genetic factors influencing the therapeutic response of valproic acid in pediatric epileptic patients.PMID 39711059Read ↗

Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy.Semantic proximity Read ↗

Evaluating the Role of Genetic Variants on first-line antiepileptic drug response in North India: Significance of SCN1A and GABRA1 Gene Variants in Phenytoin Monotherapy and its Serum Drug Levels.Semantic proximity Read ↗

Pharmacogenetics-based population pharmacokinetic analysis and dose optimization of valproic acid in Chinese southern children with epilepsy: Effect of ABCB1 gene polymorphismSemantic proximity Read ↗

Effects of UGT1A6 and GABRA1 on Standardized Valproic Acid Plasma Concentrations and Treatment Effect in Children With Epilepsy in China.Semantic proximity Read ↗

Population pharmacokinetics of valproic acid in epileptic children: Effects of clinical and genetic factors.Semantic proximity Read ↗

Association of SCN1A, SCN2A, and UGT2B7 Polymorphisms with Responsiveness to Valproic Acid in the Treatment of Epilepsy.Semantic proximity Read ↗

Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model.Semantic proximity Read ↗

Effects of UGT2B7, SCN1A and CYP3A4 on the therapeutic response of sodium valproate treatment in children with generalized seizures.Semantic proximity Read ↗

Association of genetic variants in six candidate genes with valproic acid therapy optimization.Semantic proximity Read ↗

Effects of SCN1A and SCN2A polymorphisms on responsiveness to valproic acid monotherapy in epileptic children.Semantic proximity Read ↗

Pharmacogenetics of anti-seizure medications in Arab countries: a comprehensive reviewSemantic proximity Read ↗

Polymorphisms in the Drug Transporter Gene ABCB1 Are Associated with Drug Response in Saudi Epileptic Pediatric PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.